Tarsus Pharmaceuticals CEO Bobak Azamian sells $1.16 million in stock

Published 21/03/2025, 02:50
Tarsus Pharmaceuticals CEO Bobak Azamian sells $1.16 million in stock

Bobak Azamian, the President, CEO, and Board Chair of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), recently sold shares of the company’s stock valued at approximately $1.16 million. The transactions, which took place over three days from March 18 to March 20, involved the sale of 24,216 shares at prices ranging from $46.29 to $50.11 per share. The sales come amid a strong performance period for Tarsus, with the stock up nearly 45% over the past six months and currently trading at $49.91.

These sales were executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units, as mandated by Tarsus Pharmaceuticals’ policy. Following these transactions, Azamian holds 53,635 shares directly and an additional 830,106 shares indirectly through the Bobak Azamian Living Trust. According to InvestingPro data, analysts maintain a bullish outlook on TARS, with price targets ranging from $45 to $85 per share.

The sales were not discretionary decisions by Azamian but were required under the company’s election to satisfy tax obligations through a "sell to cover" transaction. InvestingPro analysis indicates the stock is currently trading near its Fair Value, with additional insights and 8 more ProTips available to subscribers.

In other recent news, Tarsus Pharmaceuticals completed a substantial stock offering, raising approximately $134.8 million in net proceeds. This capital injection is intended to support the company’s research and development efforts, as well as general corporate purposes. In a separate announcement, Tarsus launched another public offering of $100 million, with underwriters given an option to purchase additional shares worth $15 million, although the final terms are yet to be determined. Analysts from Jefferies have raised Tarsus’s stock target to $58, maintaining a Buy rating, citing the company’s strong financial performance and potential for significant revenue growth. Similarly, Guggenheim increased the price target to $78, following Tarsus’s impressive sales figures, particularly for its product Xdemvy, which exceeded expectations.

H.C. Wainwright also kept a Buy rating, with a price target of $73, despite some investor concerns over increased marketing and R&D expenses. The firm expressed confidence in Tarsus’s long-term revenue outlook, noting its strong growth potential and market position. These developments reflect a positive outlook from multiple analyst firms, highlighting Tarsus Pharmaceuticals’ strategic initiatives and anticipated growth trajectory. Investors are keeping a close watch on the company’s progress as it continues to make strides in its financial and operational goals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.